Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 652-661

  Chitta, Kasyapa S ^a   Khan, A Nazmul H ^a   Ersing, Noreen ^a   Swaika, Abhisek ^a   Masood, Aisha ^a   Paulus, Aneel ^a   Qadeer, Abdul ^a   Advani, Pooja ^b   Sher, Taimur ^b   Miller, Kena C ^b   Lee, Kelvin ^a,c   Chanan Khan, Asher A ^a,b  

^a Department of Cancer Biology ^*  (United States)

^b MAYO CLINIC   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Azadirachta indica; CLL; Neem; NLE

Indexed keywords

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS INDUCING FACTOR; AUTOPHAGY; AZADIRACHTA; CELL NUCLEUS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM STAGING; PLANT EXTRACTS; PLANT LEAVES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894429878     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.807927     Document Type: Article

References (47)

1. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007;139:809-819.
2. Wierda WG, Chiorazzi N, Dearden C, et al. Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk 2010;10:369-378.
3. Hallek M, Pilug N. Chronic lymphocytic leukemia. Ann Oncol 2010;21(Suppl. 7):viil54-viil64.
4. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841-894.
5. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006;11:21-30.
6. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
7. Shanafelt ID. Predicting clinical outcome in CLL: how and why. Hematology Am Soc Hematol Educ Program 2009:421-429.
8. Keating MJ, O'Brien 5, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.
9. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
10. Hallek M, Fingerle-Rowson G, FinkA-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (Os) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study Group. Blood 2009;1 14(Suppl. 1): Abstract 535.
11. Hillmen P, Skotnicki AB, Robak I, et al. Alemtuzumab compared with chiorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
12. I(nauf WIJ, Lissichkov I, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
13. Roman \4 Billard C, I(ern C, et al. Analysis of resveratrolinduced apoptosis in human B-cell chronic leukaemia. Br J Haematol 2002;1 17:842-85 1.
14. Shanafelt ID, Call TG, Zent CS, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009;27:3808-3814.
15. Balakrishnan K, Wierda WG, I(eating MJ, et al. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-1980.
16. Brahmachari G. Neem-An omnipotent plant: a retrospection. Chembiochem 2004;5:408-421.
17. Priyadarsini RV, Murugan RS, Sripriya P, et al. The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondriamediated apoptosis in human cervical cancer (HeLa) cells. Free Radic Res 2010;44:624-634.
18. Manikandan P, Anandan R, Nagini S. Evaluation of Azadirachta indica leaf fractions for in vitro antioxidant potential and protective effects against H202-induced oxidative damage to pBR322 DNA and red blood cells. J Agric Food Chem 2009;57:6990-6996.
19. Harish Kumar G, Vidya Priyadarsini R, Vinothini G, et al. The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis. Invest New Drugs 2010;28:392-401.
20. Priyadarsini RV, Manikandan P, Kumar GH, et al. The neem limonoids azadirachtin and nimbolide inhibit hamster cheek pouch carcinogenesis by modulating xenobiotic-metabolizing enzymes, DNA damage, antioxidants, invasion and angiogenesis. Free Radic Res 2009;43:492-504.
21. Harish Kumar G, Chandra Mohan Ky, Jagannadha Rao A, et al. Nimbolide a limonoid from Azadirachta indica inhibits proliferation and induces apoptosis of human choriocarcinoma (BeWo) cells. Invest New Drugs 2009;27:246-252.
22. Roy MK, Kobori M, Takenaka M, et al. Antiproliferative effect on human cancer cell lines after treatment with nimbolide extracted from an edible part of the neem tree (Azadirachta indica). Phytother Res 2007;21:245-250.
23. Vinothini G, Manikandan P, Anandan R, et al. Chemoprevention of rat mammary carcinogenesis by Azadirachta indica leaf fractions: modulation of hormone status, xenobiotic-metabolizing enzymes, oxidative stress, cell proliferation and apoptosis. Food Chem Toxicol 2009;47:1852-1863.
24. Mandal-Ghosh I, Chattopadhyay U, Baral R. Neem leaf preparation enhances Thi type immune response and anti-tumor immunity against breast tumor associated antigen. Cancer Immun 2007;7:8.
25. Subapriya R, Kumaraguruparan R, Nagini S. Expression of PCNA, cytokeratin, Bcl-2 and p53 during chemoprevention of hamster buccal pouch carcinogenesis by ethanolic neem (Azadirachta indica) leaf extract. Clin Biochem 2006;39:1080-1087.
26. Chanan-I(han A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 2005;19:213-221.
27. Moreira JN, Santos A, Simoes S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 2006; 1:2 17-235.
28. Chandra J, Tracy J, Loegering D, et al. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 2006;107:2501-2506.
29. Patel MP, Masood A, Patel PS, et al. Targeting the Bcl-2. Curr Opin Oncol 2009;21:516-523.
30. Kang MH, Reynolds CR Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-1132.
31. Levine B, Sinha 5, I(roemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008;4:600-606.
32. I(roemer C, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007;87:99-163.
33. Sithisarn P, Supabphol R, Gritsanapan W. Antioxidant activity of Siamese neem tree (VP1209). J Ethnopharmacol 2005;99:109-112.
34. Subapriya R, Nagini S. Medicinal properties of neem leaves: a review. Curr Med Chem Anticancer Agents 2005;5:149-146.
35. Glick D, Barth 5, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010;221:3-12.
36. Noda T, Fujita N, Yoshimori T. The late stages of autophagy: how does the end begin? Cell Death Differ 2009;16:984-990.
37. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008;10:676-687.
38. Gupta SC, Prasad 5, Reuter 5, et al. Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents. J Biol Chem 2010;285:35406-35417.
39. Gupta SC, Reuter 5, Phromnoi K, et al. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. Biol Chem 2011;286:1134-1146.
40. Yu SW, Wang Y, Frydenlund DS, et al. Outer mitochondrial membrane localization of apoptosis-inducing factor: mechanistic implications for release. ASN Neuro 2009;1(5). ph: e00021.
41. Chung 5, Yao H, Caito 5, et al. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 2010;501: 79-90.
42. ha YL, Li 1, Qin ZH, et al. Autophagic and apoptotic mechanisms of curcumin-induced death in 1(562 cells. J Asian Nat Prod Res 2009;1 1:918-928.
43. Li J, Qin Z, Liang Z. The prosurvival role of autophagy in resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer 2009;9:215.
44. Sinha 5, Colbert CL, Becker N, et al. Molecular basis of the regulation ofBeclin 1-dependent autophagybythe gamma-herpesvirus 68 Bcl-2 homolog Mu. Autophagy 2008;4:989-997.
45. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-9040.
46. Maiuri MC, Galluzzi L, Morselli E, et al. Autophagy regulation by p53. Curr Opin Cell Biol 2010;22:181-185.
47. Eisenberg-Lerner A, Bialik 5, Simon HU, et al. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16:966-975.